Diagnostic medical imaging agents and products: Lantheus Holdings, Inc. (LNTH)

Lantheus Holdings, Inc. (NASDAQ: LNTH), founded in 1956, headquartered in North Billerica, Massachusetts, has 612 full-time employees. It develops, manufactures and commercializes diagnostic medical imaging agents and products worldwide to assist clinicians in diagnosing and treating cardiovascular diseases and other diseases.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

Lantheus Holdings, Inc. (LNTH)

Lantheus has always played an important role in developing the field of medical imaging. Over the past 60 years, Lantheus Holdings has helped doctors improve patient care through a wide range of imaging agent products and products that can illuminate the heart, brain, lungs and other organs. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

Dr. Edward Shapiro is the initiator of the "Peace Atom Initiative", and an innovator in the use of radioisotopes in medicine and science. He co founded New England Nuclear (NEN) with Seymour Rothschild in 1956. The company has grown into a leader in diagnostic imaging. In 1981, the company was E.I. du Pont de Nemours and Company (DuPont) buy. Bristol Myers Squibb (BMS) then acquired the diagnostic medical imaging business after acquiring DuPont Pharmaceutical in 2001. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

In 2008, BMS Medical Imaging was acquired by Avista Capital Partners, a private equity company headquartered in New York, and officially renamed as Lantheus Medical Imaging. In June 2015, the parent company Lantheus Holdings [LNTH] became a listed company on NASDAQ. In 2020, Lantheus acquired Progenics Pharmaceuticals. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

The main products of Lantheus Holdings, Inc. include: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

1. DEFINITY -- a microbubble contrast agent used for cardiac ultrasound examination;
2. TechneLite - a generator that provides nuclear materials for nuclear medical procedures;
3. Xenon - xenon, a radioactive drug gas used to evaluate lung function and image cerebral blood flow;
4. Neurolite - injection that can be used to identify areas in the brain that block or reduce blood flow due to stroke;
5. Cardiolite - an injectable tech labeled imaging agent for myocardial perfusion imaging (MPI) procedures;
6. FDG - a fluoro18 radiolabeled imaging agent used to identify and characterize tumors in patients undergoing tumor diagnosis procedures;
7. Cobalt (Co 57) - cobalt (Co 57), a non pharmaceutical radiochemical substance;
8. In addition, Lantheus also provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, for MPI research to detect cardiovascular diseases; Gallium Ga 67， Used to detect various infections and cancerous tumors; Quadramet， A therapeutic product for treating severe bone pain associated with metastatic bone lesions;
9. Moreover, Lantheus is developing Flurpiridaz F 18, which is in the phase III clinical trial to evaluate the blood flow to the heart; And LMI 1195, in the phase III clinical trial of diagnosis and treatment follow-up of neuroendocrine tumors.

Lantheus Holdings, Inc. sells its products to radiation pharmacies, integrated delivery networks, hospitals, clinics and group clinics. Lantheus has reached a strategic cooperation and licensing agreement with NanoMab Technology Limited, aiming to provide imaging biomarker research tools for pharmaceutical companies and academic centers engaged in research and development of PD-L1 immunotumor therapy. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

On February 6, 2023, Lantheus Holdings (NASDAQ stock code: LNTH) said on Monday that it had acquired Cerveau Technologies, a company that uses molecular imaging to help develop treatments for Alzheimer's disease and other cognitive disorders. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lnth.html

Lantheus Holdings, Inc. (LNTH) US equity investment